Why is endostatin not used?

Why is endostatin not used?

The company couldn’t handle the high volume of endostatin needed for trials to continue, and its production was expensive. Meanwhile, the drug wasn’t advancing to phase III trials because phase II studies mostly showed no tumor response.

What is human endostatin?

Endostatin is a cleaved product of the carboxyl-terminal domain of collagen XVIII. It functions as an anti-angiogenic cytokine that is expressed in various organs especially with high levels in liver, lung, and kidney. Endostatin inhibits angiogenesis by blocking the pro-angiogenic activities of VEGF and FGF-basic.

What is the human endostatin gene?

A recombinant human proteolytic fragment of the C-terminal end of type XVIII collagen. Endostatin induces microvascular endothelial cell apoptosis and inhibits endothelial proliferation and angiogenesis, which may result in a reduction in tumor burden.

Is endostatin FDA approved?

Endostatin has been approved by the US Food and Drug Administration (FDA) for the treatment of NV-related cancer; thus, it may be an additional drug that can be added to anti-VEGF therapy to treat corneal NV- and lymphangiogenesis-related disorders.

Is endostatin a protein?

Background: Endostatin. Endostatin, an endogenous non‑glycosylated inhibitor of endothelial cell proliferation and angiogenesis, is an approximately 181 amino acid (aa), 20 kDa proteolytic fragment of the C‑terminal non‑collagenous domain of type XVIII collagen (1, 2).

Where is endostatin produced?

Endostatin is a 184-amino acid C-terminal monomeric fragment of the noncollagenous domain of type XVIII collagen. Recombinant endostatin produced in baculovirus infected insect cells and in bacteria inhibited endothelial cell proliferation, but in initial studies had no effect on tumor cell proliferation in vitro.

What type of substances are angiostatin and endostatin?

Angiostatin and endostatin: endogenous inhibitors of tumor growth.

When was endostatin FDA approved?

In September 2005, endostatin (Endostar) was approved by the State FDA in China for the treatment of non-small-cell lung cancer [3]. In addition, other drugs previously approved by the FDA for other uses have recently been found to have antiangiogenic activity.